Michelle Petri|Mohammad Naqibuddin|Margaret Sampedro|Roald Omdal|Kathryn A. Carson
Memantine in Systemic Lupus Erythematosus: A Randomized, Double-Blind Placebo-Controlled Trial
Johns Hopkins University|Johns Hopkins Medicine|Johns Hopkins University|Johns Hopkins University|Stavanger University Hospital|Johns Hopkins University
cognitive impairment affects 80 systemic lupus erythematosus sle patients within 10 years diagnosis memantine seronergic receptor nicotine acetylcholine receptor antagonist acts glutamatergic system nmda receptor used treat dementia investigated whether benefit sle cognitive impairment randomized doubleblind placebocontrolled singlecenter 12week trial memantine titrated 20 mgd performed using 21 randomization ratio 51 sle patients primary outcome measures change automated neuropsychological assessment metrics throughput scores 12 weeks statistically significant differences treatment groups change baseline automated neuropsychological assessment metrics throughput scores 6 12 weeks american college rheumatology cognitive battery statistically significant findings controlled oral word association tests words 6 12 weeks 12 weeks memantine group exhibited greater improvement compared placebo group 36 18 vs 05 38 words p 003 subset analysis limited patients scored 1 standard deviation normal controls baseline significant differences treatment groups found first clinical trial memantine sle patients treated memantine exhibit significant improvement cognitive performance compared placebo group regardless degree impairment baseline exception controlled oral word association